FDA panel endorses ketamine nasal spray for depression
Mental Health Weekly February 25, 2019 DOI: 10.1002/mhw.31789 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | Ketamine nasal spray |
| Topics | Depression Esketamine Ketamine |
| Key points | An FDA advisory committee recommended approval of a ketamine nasal spray for adults with treatment-resistant depression, and recent research is cited as showing ketamine treatment gaining traction as an effective depression treatment. |
Abstract
A Food and Drug Administration (FDA) advisory committee earlier this month recommended the approval of a ketamine nasal spray treatment for adults with treatment‐resistant depression. Recent research has shown that ketamine treatment is gaining traction as an effective treatment for people struggling with depression.